{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:44:17Z","timestamp":1792244657070,"version":"4.4.0"},"reference-count":81,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Interv Neuroradiol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Bevacizumab (BCZ), commercially known as Avastin, is a monoclonal antibody that targets vascular endothelial growth factor (VEGF). Initially recognized as a breakthrough in oncology, it has since gained FDA approval for various ocular conditions and more recently, for the treatment of glioblastoma multiforme (GBM). Bevacizumab's ability to inhibit excessive neovascularization suggests it may have a potential role in treating chronic subdural hematomas (cSDH). Recent studies have shown that the pathophysiology of cSDH is more complex than previously understood, with VEGF concentrations in subdural fluid significantly exceeding those in serum, contributing to the high recurrence rates. Intra-arterial administration of bevacizumab has shown promising results in recent case series against chronic subdural hematoma, and may be a viable alternative to middle meningeal artery embolization. If successful, this treatment could significantly decrease the rate of recurrence and result in lower rates of severe neurological complications such as visual loss. This literature review explores the connection between bevacizumab and cSDH, focusing on the pharmacological, safety, and delivery aspects of this approach while summarizing the current evidence supporting its use.<\/jats:p>","DOI":"10.1177\/15910199241298727","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T05:31:51Z","timestamp":1732167111000},"page":"1954-1965","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Bevacizumab: The future of chronic subdural hematoma"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0631-5436","authenticated-orcid":false,"given":"Yash","family":"Verma","sequence":"first","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Abdelghaffar","sequence":"additional","affiliation":[{"name":"School of Medicine, Royal College of Surgeons in Ireland, Busaiteen, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onam","family":"Verma","sequence":"additional","affiliation":[{"name":"Government Medical College and Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Gajjar","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-3023","authenticated-orcid":false,"given":"Sherief","family":"Ghozy","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-0040","authenticated-orcid":false,"given":"David F","family":"Kallmes","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030034"},{"key":"e_1_3_2_3_2","unstructured":"Gerriets V Bevacizumab Kasi A. 2024."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26144127"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03851-2"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2020-000114"},{"key":"e_1_3_2_7_2","article-title":"Intraarterial bevacizumab administration through the middle meningeal artery for chronic subdural hematoma","volume":"3","author":"Khalife J","year":"2023","unstructured":"Khalife J, Tonetti DA, Shaikh H, et al. Intraarterial bevacizumab administration through the middle meningeal artery for chronic subdural hematoma. Stroke Vasc Interv Neurol 2023; 3: e000722. https:\/\/www.ahajournals.org\/doi\/10.1161\/SVIN.122.000722","journal-title":"Stroke Vasc Interv Neurol"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.36473"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911423031"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.08.002"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0317"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.11.015"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3171\/2018.12.JNS183035"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcw231"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3171\/2021.3.JNS21281"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0881-y"},{"key":"e_1_3_2_17_2","first-page":"23","article-title":"The etiology of pachymeningitis hemorrhagica interna in infants","author":"Schwartz AB","year":"1916","unstructured":"Schwartz AB. The etiology of pachymeningitis hemorrhagica interna in infants. Am J Dis Child 1916; XI: 23\u201332.","journal-title":"Am J Dis Child"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-022-00570-y"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090149"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112787"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.05.037"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1366238"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2001.95.2.0256"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1994.81.6.0910"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2021.04.052"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1987.67.5.0677"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-09064-z"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.02.074"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13971"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70477-1"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308345"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02253-6"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273940802596534"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2009.02.004"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2010.03.004"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000244380.34082.67"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0664-8"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1846-6"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/405735"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.2.84"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199904000-00117"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/159101991001600109"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1161\/SVIN.123.000906"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/SVIN.122.000490"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1500"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03435-6"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.950167"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.3340\/jkns.2018.0180"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-014469"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2021-017900"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.041301"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2017.1273345"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181a2f42a"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.07.033"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/26\/25\/255102"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-020-00722-7"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2947"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3055"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006278"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2018.1478563"},{"issue":"5","key":"e_1_3_2_66_2","article-title":"Intra-arterial selective bevacizumab administration in the middle meningeal artery for chronic subdural hematoma: an early experience in 12 hemispheres","volume":"4","author":"Khalife","year":"2024","unstructured":"Khalife, et al. Intra-arterial selective bevacizumab administration in the middle meningeal artery for chronic subdural hematoma: an early experience in 12 hemispheres. AHA 2024; 4(5): e001409.","journal-title":"AHA"},{"key":"e_1_3_2_67_2","first-page":"93","article-title":"Therapeutic efficacy of drilling drainage combined with intraoperative middle meningeal artery occlusion in the management of chronic subdural hematoma: a clinical study.","volume":"47","author":"Sun T","unstructured":"Sun T, et al. Therapeutic efficacy of drilling drainage combined with intraoperative middle meningeal artery occlusion in the management of chronic subdural hematoma: a clinical study. Neurosurg Rev 25 Jun. 2024; 47: 93.","journal-title":"Neurosurg Rev"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-016-0704-0"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2024.06.036"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1136\/neurintsurg-2021-018327"},{"key":"e_1_3_2_71_2","unstructured":"Drug Approval Package. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/STN-125085_Avastin.cfm (accessed 26 July 2024)."},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033852"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.10.010"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.026"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.01.028"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1507735"},{"key":"e_1_3_2_77_2","article-title":"Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials. S\u00f8rensen TL, editor","volume":"9","author":"Wu B","year":"2014","unstructured":"Wu B, Wu H, Liu X, et al. Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials. S\u00f8rensen TL, editor. PLoS ONE 2014; 9: e101253. https:\/\/dx.plos.org\/10.1371\/journal.pone.0101253 (accessed 26 July 2024).","journal-title":"PLoS ONE"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11043-6"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1391-8"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.271242"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.07.015"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-023-00314-w"}],"container-title":["Interventional Neuroradiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15910199241298727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15910199241298727","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15910199241298727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:47:42Z","timestamp":1786164462000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15910199241298727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/15910199241298727"],"URL":"https:\/\/doi.org\/10.1177\/15910199241298727","relation":{},"ISSN":["1591-0199","2385-2011"],"issn-type":[{"value":"1591-0199","type":"print"},{"value":"2385-2011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}